Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652942 | 0.90 | GAA (0.46) | GAAMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL2653981 | 0.90 | GAA (0.46) | GAAMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL2652387 | 0.88 | KIT (0.39) | MAPTKDM4EALDH1A1RAB9AMEN1 | |
| SCHEMBL2966414 | 0.85 | GAA (0.42) | GAAMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL2659592 | 0.85 | GAA (0.45) | GAAMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL2652685 | 0.84 | GABRA1 (0.47) | MAPTKDM4EALDH1A1RAB9AMEN1 | |
| SCHEMBL2654799 | 0.84 | FGFR1 (0.51) | GAAMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL13202760 | 0.82 | GAA (0.43) | GAAMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL2650177 | 0.82 | GAA (0.43) | GAAMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL2977332 | 0.82 | KIT (0.39) | GAAMAPTKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | claimed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | claimed |
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | disclosed |
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | disclosed |
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | disclosed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | disclosed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | disclosed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | disclosed |
| EP-1874758-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111516-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | GABRB2, GABRB1, GABRB3 | GAA 1174/4885MAPT 2156/4885KDM4E 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.